logo
logo

Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing To Advance Next-Generation Precision Editing Therapeutics

Nov 09, 2021•almost 4 years ago

Amount Raised

$215 Million

Round Type

series b

Cambridge

Description

Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the completion of an oversubscribed and up-sized $215 million Series B financing. Including this round, the Company has raised over $300 million to date.

Company Information

Company

Arbor

Location

Cambridge, Maryland, United States

About

We welcome Dr. Yu to the board and look forward to his contributions as the company works toward deploying these new therapies to treat patients in the near future.”

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech